Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide pharmacodynamics in obesity
NCT00444561Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2004
- Primary completion
- May 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pramlintide in obesity (4 arms), sponsored by AstraZeneca. Primary endpoints: Change in Body Weight at 73 Days and Change in Food Intake at 73 Days. Started Aug 2004; status: completed.
02
Drugs
pramlintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00444561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00444561.